A stochastic model for primary HIV infection: Optimal timing of therapy

AIDS

Volumn 13, Issue 3, 1999, Pages 351-357

  Ribeiro, Ruy M ^a   Bonhoeffer, Sebastian ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ETH ZURICH   (Switzerland)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Primary infection; Resistant mutant; Stochastic model; Timing of therapy

Indexed keywords

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; SIMULATION; STOCHASTIC MODEL; VIRUS MUTANT;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; STOCHASTIC PROCESSES; TIME FACTORS; VIREMIA; VIRUS REPLICATION;

EID: 0032968677     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902250-00007     Document Type: Article

References (38)

1. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243:1731-1734.
2. Boucher CAB, Lange JMA, Miedema FF, et al.: HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992, 6:1259-1264.
3. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
4. Markowitz M, Mo HM, Kempf DJ, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
5. De Jong MD, Veenstra J, Stilianakis NJ, et al.: Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA 1996, 93:5501-5506.
6. Ho DD: Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
7. BHIVA Guidelines Co-ordinating Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
8. Moyle GJ, Gazzard BG, Cooper DA, Gatell J: Antiretroviral therapy for HIV infection. Drugs 1998, 55:383-404.
9. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. JAMA 1997, 277:1962-1969.
10. DELTA Co-ordinating Committee: Delta: a randomized double- blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV- infected individuals. Lancet 1996, 348:283-291.
11. Perrin L and Kinloch-De Loes S: Therapeutic interventions in primary HIV infection. J AIDS Hum Retrovir 1995, 10:S69-76.
12. Rachlis AR, Zarowny DP: Guidelines for antiretroviral therapy for HIV infection. Can Med Assoc J 1998, 158:496-505.
13. Carpenter C, Feinberg M, Aubry W, et al.: Report of the NIH panel to define principles of therapy of HIV infection. Ann Intern Med 1998, 128:1057-1078.
14. Anderson J, Armstead R, Baker AC, et al.: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998, 128:1079-1100.
15. Zhu TF, Mo HM, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993, 261:1179-1181.
16. Karlsson AC, Lindback S, Gaines H, Sonnerborg A: Characterization of the viral population during primary HIV-1 infection. AIDS 1998, 12:839-847.
17. Bonhoeffer S, Nowak MA: Pre-existence and emergence of drug resistance in HIV-1 infection. Proc R Soc B 1997, 264:631-637.
18. Bonhoeffer S, May RM, Shaw GM, Nowak MA: Virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997, 94:6971-6976.
19. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3:533-540.
20. + repertoire during antiviral therapy. Nat Med 1998, 4:215-221.
21. Pantaleo G, Demarest JF, Schacker T, et al.: The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997, 94:254.
22. Koup RA, Safrit JT, Cao YZ, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
23. Borrow P, Lewicki H, Wei XP, et al.: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3:205-211.
24. Legrand E, Pellegrin I, Neau D, et al.: Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. AIDS Res Hum Retroviruses 1997, 13:1383-1394.
25. Tindall B, Carr A, Goldstein D, Penny R, Cooper DA: Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune-response [letter]. AIDS 1993, 7:127-128.
26. Tindall B, Gaines H, Imrie A, et al.: Zidovudine in the management of primary HIV-1 infection. AIDS 1991, 5:477-484.
27. Perrin L, Rakik A, Yerly S, et al.: Combined therapy with zidovudine and L-697,661 in primary HIV-infection. AIDS 1996, 10:1233-1237.
28. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995, 333:408-413.
29. Wei XP, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
30. Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1993, 373:123-126.
31. Perelson AS, Essunger P, Cao YZ, et al.: Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997, 387:188-191.
32. Nowak MA, Bangham CRM: Population dynamics of immune responses to persistent viruses. Science 1996, 272:74-79.
33. Ribeiro RM, Bonhoeffer S, Nowak MA. The frequency of resistant mutant virus before antiviral therapy. AIDS 1998, 12:461-465.
34. Mansky LM, Temin HM: Lower in-vivo mutation rate of human immunodeficiency virus type 1 than the predicted from the fidelity of purified reverse transcriptase. J Virol 1995, 69:5087-5094.
35. Pratt RD, Shapiro JF, McKinney N, Kwok S, Spector SA: Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury. J Infect Dis 1995, 172:851-854.
36. + cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses 1997, 13:1375-1381.
37. Nowak MA, Lloyd AL, Vasquez GM, et al.: Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997, 71:7518-7525.
38. Phillips AN: Reduction of HIV concentration during acute infection - Independence from a specific immune-response. Science 1996, 271:497-499.